Navigation Links
Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo

CHICAGO, According to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings, patients treated for follicular lymphoma, a slow-growing type of non-Hodgkins lymphoma, may benefit from chemotherapy followed by radioimmunotherapy.

Over 90 percent of study patients responded completely to the treatment and since only a short-course of chemotherapy was used, side effects were limited and well-tolerated. Radioimmunotherapy was delivered through the use of a radiolabeled monoclonal antibody specifically designed to kill lymphoma cells with the help of a radioactive atom.

We found that adding a radioactive monoclonal antibody to standard chemotherapy helped lymphoma patients achieve a higher complete response rate. We hope that this will translate into long-lasting remissions, said Samuel Jacobs, M.D., lead investigator and associate director for clinical investigations at the University of Pittsburgh Cancer Institute and UPMC Cancer Centers.

In the study, a radiolabeled monoclonal antibody called ibritumomab tiuxetan (IT) was added to CHOP-R, a standard multi-drug regimen for follicular lymphoma that consists of cyclophosphamibe, doxorubicin, vincristine, prednisone and rituximab. Investigators reported on 50 patients treated with CHOP-R, examined their responses and then treated them with IT. Sixty-eight percent of the patients had a complete response to treatment with CHOP-R. This percentage increased to 96 percent after treatment with IT.

The complete response rate was determined by both conventional CT and the use of PET, or positron emission tomographya scan that measures abnormal molecular cell activity. PET was used to determine which patients had an early complete disease response after treatment with chemotherapy alone and after treatment with IT. The researche rs found that five out of 16 patients who had a positive PET scan after the initial chemotherapy phase of treatment relapsed. Of the 34 patients whose early PET scans were negative, none have relapsed to-date.

We were surprised to find that PET was a useful tool in determining those patients who were at highest risk for their diseases to relapse. Our next step is to compare the tumor characteristics of the patients who relapsed to those who had an early complete response, said Dr. Jacobs.


'"/>




Related medicine news :

1. Lymphomas Link to Hepatitis C
2. No Lymphoma Risk From Rheumatoid Arthritis Drugs
3. New Guidelines For Assessing Lymphoma Treatment
4. A Novel Treatment for KSHV-infected Lymphomas
5. Risk of Lymphoma Increases With Hepatitis C Virus Infection
6. Study Finds Lymphoma Drug Effective Over Long Term
7. Long-term Oral Steroid Therapy Decreases Lymphoma Risk in Rheumatoid Arthritis
8. One in Three Heart Attack Patients Have No Chest Pains
9. Amphetamines Help Recovery of Stroke Patients
10. Painkillers Do Not Shorten Dying Patients Lives
11. Patients With Filariasis More Prone To HIV Infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: